文献速递冠心病血脂与心血管预防

CSL112(血浆源性载脂蛋白A-I)在急性心肌梗死后的安全性与耐受性:AEGIS-I试验

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).
PubMed 文献 · Circulation · 2016-11-15

AEGIS-I是一项多中心、随机、双盲、安慰剂对照、剂量探索的2b期试验,纳入1258例急性心肌梗死患者,随机接受CSL112 2g、6g或安慰剂每周输注4次。主要安全终点(肝事件和肾事件)发生率与安慰剂的差异均在预设非劣效界值内(肝4%、肾5%),CSL112可增加载脂蛋白A-I和胆固醇流出能力,主要不良心血管事件风险组间相似。

要点

  • 急性心肌梗死后每周输注CSL112 4次可行且耐受性良好,未观察到显著肝肾功能异常。
  • CSL112可急性增强胆固醇流出能力,效果与稳定性冠心病患者相似。
  • 主要不良心血管事件风险组间相似,需3期试验评估其降低事件潜力。

核心结论

  • 在急性心肌梗死患者中,每周4次输注CSL112可行、耐受性良好,未导致肝肾功能显著改变或其他安全问题。
  • CSL112急性增强胆固醇流出能力的作用得到确认。
  • CSL112降低主要不良心血管事件的潜在获益需在足够把握度的3期试验中评估。

研究设计与样本

  • AEGIS-I为多中心、随机、双盲、安慰剂对照、剂量探索的2b期试验。
  • 共随机化1258例心肌梗死患者,按肾功能分层,以1:1:1接受CSL112 2g、6g或安慰剂每周输注4次。
  • 91.2%的患者接受了全部4次输注。

主要发现

  • 两个CSL112剂量组与安慰剂组之间丙氨酸转氨酶或总胆红素升高的发生率差异在方案规定的非劣效界值4%以内。
  • 两个CSL112剂量组与安慰剂组之间血清肌酐升高或新需要肾脏替代治疗的发生率差异在方案规定的非劣效界值5%以内。
  • CSL112与载脂蛋白A-I和离体胆固醇流出能力的增加相关,程度与稳定性冠心病患者相似。
  • 次要疗效终点方面,各组间主要不良心血管事件复合终点的风险相似。

关键数值与推荐

  • 共同主要安全终点包括肝安全事件(丙氨酸转氨酶>3倍正常上限或总胆红素>2倍正常上限)或肾安全事件(血清肌酐>1.5倍基线值或新需要肾脏替代治疗)。
  • 肝安全事件非劣效界值为4%,肾安全事件非劣效界值为5%。
  • CSL112剂量为每剂2g或6g载脂蛋白A-I,每周输注1次,共4次。

临床怎么用

  • 对于急性心肌梗死患者,CSL112每周4次输注方案可行且耐受性良好,未观察到显著肝肾功能异常。
  • CSL112可急性增强胆固醇流出能力,但降低主要不良心血管事件的获益尚未证实,需等待3期试验结果。

局限性

  • 本研究为2b期剂量探索试验,主要评估安全性和耐受性,主要不良心血管事件为次要终点且各组相似,不足以评估疗效。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human or recombinant apolipoprotein A-I (apoA-I) has been shown to increase high-density lipoprotein-mediated cholesterol efflux capacity and to regress atherosclerotic disease in animal and clinical studies. CSL112 is an infusible, plasma-derived apoA-I that has been studied in normal subjects or those with stable coronary artery disease. This study aimed to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of CSL112 in patients with a recent acute myocardial infarction. METHODS: The AEGIS-I trial (Apo-I Event Reducing in Ischemic Syndromes I) was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial. Patients with myocardial infarction were stratified by renal function and randomized 1:1:1 to CSL112 (2 g apoA-I per dose) and high-dose CSL112 (6 g apoA-I per dose), or placebo for 4 consecutive weekly infusions. Coprimary safety end points were occurrence of either a hepatic safety event (an increase in alanine transaminase >3 times the upper limit of normal or an increase in total bilirubin >2 times the upper limit of normal) or a renal safety event (an increase in serum creatinine >1.5 times the baseline value or a new requirement for renal replacement therapy). RESULTS: A total of 1258 patients were randomized, and 91.2% received all 4 infusions. The difference in incidence rates for an increase in alanine transaminase or total bilirubin between both CSL112 arms and placebo was within the protocol-defined noninferiority margin of 4%. Similarly, the difference in incidence rates for an increase in serum creatinine or a new requirement for renal replacement therapy was within the protocol-defined noninferiority margin of 5%. CSL112 was associated with increases in apoA-I and ex vivo cholesterol efflux similar to that achieved in patients with stable coronary artery disease. In regard to the secondary efficacy end point, the risk for the composite of major adverse cardiovascular events among the groups was similar. CONCLUSIONS: Among patients with acute myocardial infarction, 4 weekly infusions of CSL112 are feasible, well tolerated, and not associated with any significant alterations in liver or kidney function or other safety concern. The ability of CSL112 to acutely enhance cholesterol efflux was confirmed. The potential benefit of CSL112 to reduce major adverse cardiovascular events needs to be assessed in an adequately powered phase 3 trial. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov. Unique identifier: NCT02108262.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Michael Gibson C, Korjian S, Tricoci P, et al. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation. 2016. PMID: 27881559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。